NeurogesX
Develops and commercializes therapies for chronic peripheral neuropathic pain.
Launch date
Employees
Market cap
-
Enterprise valuation
€4—5m (Dealroom.co estimates Mar 2012.)
San Carlos California (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
$8.4m | Series A | ||
$22.9m | Series B | ||
$35.0m | Series C | ||
$20.0m | Series D | ||
N/A | N/A | IPO | |
$25.0m | Post IPO Equity | ||
$20.2m | Post IPO Equity | ||
N/A | $980k | Seed | |
* | N/A | Acquisition | |
Total Funding | €79.3m |
Related Content
Recent News about NeurogesX
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.